Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chitosan-hyaluronate gel mixture is an experimental hybrid viscosuppressant being investigated for the treatment of temporomandibular joint (TMJ) internal derangement, specifically Wilkes Stage III or IV anterior disc displacement without reduction. The formulation combines the lubricating and anti-inflammatory properties of hyaluronic acid, a naturally occurring glycosaminoglycan in synovial fluid, with chitosan, a biocompatible polysaccharide derived from chitin known for its mucoadhesive and structural properties. This combination is intended to enhance the mechanical stability and residence time of the injection within the joint space following arthroscopic lysis and lavage, thereby reducing pain and improving joint mobility and maximum mouth opening.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chitosan-hyaluronate gel mixture.